HTA
Patients/ Views & Analysis/ Views and analysis
UK-wide whole genome sequencing for newborns is feasible – but there are some key questions to answer first
mike.hammerton@pharmaphorum.com
AstraZeneca, COVID-19, EFPIA, healthcare, HTA, NICE, sustainable healthcare
0 Comment
Patients/ Views & Analysis/ Views and analysis
What does the future of European healthcare look like?
Amanda Barrell
AstraZeneca, COVID-19, EFPIA, healthcare, HTA, NICE, sustainable healthcare
0 Comment
Patients/ Views & Analysis/ Views and analysis
How to balance the patient voice atop the shifting plates of HTA
Deep Dive/ Market Access/ Views & Analysis/ Views and analysis
Rethinking access barriers to innovation
mike.hammerton@pharmaphorum.com
ATMP, Deep Dive, Deep Dive: Market Access, Executive Insight, HTA, market access
0 Comment
Market Access/ Podcast/ Video/ Views & Analysis/ Views and analysis
Galapagos UK’s Michael Smyth on RNA-based tech: the pharmaphorum podcast
mike.smith@pharmaphorum.com
Galapagos, HTA, Michael Smyth, podcast, rna
0 Comment
Deep Dive/ Market Access/ Views & Analysis/ Views and analysis
Deep Dive: Market Access
mike.hammerton@pharmaphorum.com
Boehringer Ingelheim, Brexit, Deep Dive, digital health, HTA, market access, NICE, patient centricity, patient engagement, sales
0 Comment
Okra says AI-based drug price predictor is 90% accurate
Phil Taylor
artificial intelligence, digital, digital health, HEOR, HTA, Iqwig, machine learning, OKRA Technologies
0 Comment